Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Clinical Efficacy and Safety of Trimebutine Maleate Combined With Rabeprazole in Patients With Grade A or B Reflux Esophagitis Whose Symptoms Refractory to Rabeprazole

NCT02986685 is registered in ClinicalTrials.gov with Xijing Hospital of Digestive Diseases as lead sponsor.

NCT NCT02986685
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02986685 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Clinical Efficacy and Safety of Trimebutine Maleate Combined With Rabeprazole in Patients With Grade A or B Reflux Esophagitis Whose Symptoms Refractory to Rabeprazole
Lead sponsor
Xijing Hospital of Digestive Diseases
Phase
Phase 4
Overall status
Withdrawn
Start date
November 30, 2016
Completion date
November 30, 2017
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

refractory reflux esophagitis